Continuous glucose monitors (CGMs) have undergone a dramatic transformation in just two years, shifting from clinical devices requiring prescriptions to over-the-counter products available at retail prices. In June 2026, the FDA cleared Dexcom's Stelo CGM for children as young as two years old, marking a major milestone in how medical sensing technology reaches consumers. Parents can now purchase the device without a prescription, apply it to a toddler's arm, and track glucose levels updated every fifteen minutes for fifteen days, all through a smartphone app.

This progression from prescription-gated clinical tool to retail product happened remarkably fast. Dexcom's Stelo became the first over-the-counter CGM in FDA history when it received clearance in March 2024 for adults 18 and older who don't use insulin. The device launched in the US on August 26, 2024, priced at $99 for a two-sensor pack covering about 30 days, or $89 per month on subscription, with costs eligible for health savings accounts and flexible spending accounts. Just months later, Abbott moved into the same retail space with two OTC sensors of its own: Lingo, targeting wellness-focused adults, and Libre Rio, aimed at people with non-insulin type 2 diabetes.

The speed of this shift reflects two converging forces. First, sensor technology became cheap and accurate enough to sell profitably at consumer prices without insurance reimbursement. Second, the FDA created a new regulatory category for OTC integrated CGMs, opening a pathway that didn't exist before March 2024. Hardware economics and regulatory approval arrived in the same window, and companies launched products before anyone had settled what they were actually worth.

What's Driving the Move to Over-the-Counter Glucose Monitors?

The addressable market for these devices is enormous. The CDC and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) count 38.1 million US adults with diabetes and 97.6 million adults with prediabetes, more than one in three adults. Even before a single wellness user buys a sensor, that clinical base is larger than the population of most countries. Abbott's Diabetes Care franchise reached $7.998 billion in 2025, up 17.5%, with FreeStyle Libre alone hitting $2.0 billion in a single quarter. Dexcom, essentially a pure-play CGM company, posted $4.662 billion in 2025, up 16%.

The two companies that dominate the US CGM market split the over-the-counter opportunity along a revealing line. Stelo and Libre Rio point at the tens of millions of people who already have a glucose problem. Lingo points at everyone else: the curious, the optimizing, the worried-well. That second pool is what makes Wall Street excited and clinicians wary.

Pricing strategies reveal how each company reads the market. Abbott's Lingo six-pack at $249 works out to about $41.50 per sensor, cheaper per unit than its single-sensor pricing, a structure designed to pull casual users into a habit. Dexcom's Stelo subscription at $89 per month targets someone who expects to wear a sensor more or less continuously. Both companies bet on recurring consumption rather than one-time purchases, using the same razor-and-blades model that built the prescription CGM business. A 14- or 15-day sensor that must be replaced roughly two to three times per month turns a single sale into an annuity.

How Are Companies Expanding Beyond Just Hardware?

As CGM sensors have become commoditized, the competitive battleground has shifted from hardware to software, data interpretation, and behavioral coaching. Dexcom's acquisition of Nutrisense, announced at the American Diabetes Association's Scientific Sessions in June 2026, exemplifies this transition. By integrating nutrition coaching and behavioral modification into its core offerings, Dexcom is signaling that the future lies in building full metabolic-health ecosystems rather than relying on sensor technology alone.

Dexcom launched its first generative AI feature in glucose biosensing for Stelo customers in 2024, a coaching layer that turns raw data into daily nudges. The company also introduced a completely reimagined Stelo app experience that received FDA clearance in May 2026, with select users gaining early access on June 5, 2026, ahead of a full rollout scheduled for later in the summer. The updated app launches with proactive AI coaching, pattern recognition, and personalized weekly summaries designed to reveal the direct connection between glucose levels and physical sensations.

Dexcom's CEO Jake Leach emphasized the company's broader vision. "These initiatives are designed to build a connected ecosystem that delivers real-time observations, personalized support, and behavioral coaching," he stated. The Nutrisense acquisition allows Dexcom to offer direct integration of dietitian services, transition to a high-margin subscription model, and establish preventative health pathways before patients escalate to insulin dependency.

Jake Leach

The clinical diabetes technology market is undergoing its own software and hardware integration. Insulet updated the software algorithm for its Omnipod 5 patch pump, introducing a lower target glucose option of 100 mg/dL to provide clinical flexibility in diverse care settings. Crucially, Insulet established compatibility between the Omnipod 5 and Abbott's latest Freestyle Libre 3 Plus sensor, demonstrating that the market is moving toward cross-manufacturer interoperability.

Steps to Understanding the Wellness CGM Market

• Market Segmentation: Companies target different audiences with different products. Stelo and Libre Rio focus on people with existing glucose problems, while Lingo targets healthy people interested in metabolic optimization and wellness tracking.
• Pricing Models: Most OTC CGMs use subscription or recurring purchase models rather than one-time sales, with sensors lasting 14 to 15 days and requiring replacement two to three times per month.
• Software Competition: As hardware becomes commoditized, companies compete on AI coaching, behavioral interventions, dietitian access, and personalized insights rather than sensor accuracy alone.
• Regulatory Pathways: The FDA's creation of the OTC integrated CGM category in 2024 opened a new regulatory on-ramp that enabled rapid commercialization without traditional clinical trial requirements for some products.

Does Wellness CGM Actually Help Healthy People?

Here's where the story gets complicated. Marketing says the wellness CGM is for the metabolically curious person who wants to see how a bagel spikes their glucose and adjust accordingly. The clinical answer, as of late 2025, is that nobody can yet prove this helps a healthy person at all.

The retail channel changes the buyer dynamic fundamentally. A prescription CGM is sold to a clinician who decides a patient needs it. An OTC sensor is sold to a person who decides they want it. Marketing, not medical necessity, drives the second sale. That shift is what unsettles clinicians: a tool built and validated for disease management is now being merchandised to the well.

Dexcom's acquisition of Nutrisense and the launch of the reimagined Stelo app with AI coaching represent an attempt to bridge this gap by providing behavioral support and personalized insights. However, the clinical evidence supporting these interventions in healthy users remains limited. The company is betting that software and coaching can transform a data stream into meaningful health improvements, but that bet has not yet been validated in rigorous studies.

The economic reality is telling. Neither Dexcom nor Abbott breaks out OTC revenue separately in their earnings reports, which itself signals that retail sensors are still small relative to the prescription business that pays the bills. The validated outcomes and durable revenue still sit almost entirely with incumbents and reimbursed connected care, not with the wrist or the retail shelf.

What's clear is that the medical device industry has fundamentally changed how it brings sensing technology to consumers. Capability that used to require a clinic, a lab order, and a trained reader now ships in a blister pack. A $400 watch tells a healthy adult they may have sleep apnea. A toddler can wear a glucose sensor without a doctor's involvement. Whether that reach translates into meaningful health improvements for people without diabetes remains the open question that will define the next chapter of this market.

" }